ACAN · proposed sole-source⚠️ Closing in 5 days

Calcium Trisodium Pentetate (Ca-DTPA) ampoules

National DefenceDrugs and Pharmaceutical Products
☆ Save tender

Solicitation summary

FieldDetails
BuyerNational Defence
CategoryDrugs and Pharmaceutical Products
Published2026-11-10
Closing Date2026-11-25
Procurement methodACAN · proposed sole-source Advance Contract Award Notice: the buyer intends to award to a pre-identified supplier. Other suppliers may only submit a statement of capabilities before the closing date.
RegionCanada
Published
Closing Date
Region
Canada

Description

NOTICE OF PROPOSED PROCUREMENT The Department of National Defence (DND), through the Strategic Medical Countermeasures Program (SMCP) on behalf of the Canadian Forces Health Services Group (CF H Svcs Gp), has a requirement for the supply of Calcium Trisodium Pentetate (Ca-DTPA) ampoules for the treatment of Canadian Armed Forces (CAF) personnel who may have been exposed to radioactive contamination involving transuranic elements. The Ca-DTPA product must consist of sterile Calcium Trisodium Pentetate solution for injection, containing approximately 1,000 mg to 1,055 mg of active ingredient in a 5 mL ampoule suitable for intravenous administration. The product is intended for use as a medical countermeasure to enhance the elimination of internally deposited radioactive transuranic elements, including plutonium, americium and curium, following confirmed or suspected radiological exposure. The product must meet all applicable regulatory, quality assurance, packaging, labelling and shelf-life requirements specified in the solicitation documents. The initial requirement consists of the supply of 250 Ca-DTPA ampoules for delivery no later than 1 March 2027. The resulting contract is anticipated to be valid from contract award date to 31 March 2031 and includes additional scheduled deliveries of 250 ampoules in Fiscal Year 2027-2028 and 250 ampoules in Fiscal Year 2028-2029. The contract will also include an option for up to an additional 500 ampoules exercisable during the contract period. This procurement will be conducted through an Advance Contract Award Notice (ACAN). The Government of Canada has identified Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG as the only supplier currently known to satisfy the operational, clinical and technical requirements associated with this requirement. Suppliers that consider themselves fully qualified and capable of meeting the complete requirement may submit a Statement of Capabilities during the posting period. The Crown retains the rights to negotiate with suppliers on any procurement. Documents may be submitted in either official language of Canada. Barring any applicable trade agreement exceptions or other legal restrictions, eligible suppliers may participate in this solicitation process. NOTE TO SUPPLIERS: Procurement Assistance Canada offers seminars to businesses interested in learning how to sell goods and services to the Government of Canada. These seminars are provided free of charge.

Bid / no-bid fit

Sign in to see how well this tender fits your company, with reasons.

Tender brief & compliance checklist

No document text is available yet; a brief would use the notice text only.

Solicitation documents

Read and download the solicitation documents (RFP, statement of work, bid forms and amendments) on the official notice.

Open the official notice ↗

Price benchmark

Range $4,000 – $218.2M · median $1.8M · n=99 · inferred from published winners in the same codes/department

Incumbency

Inferred rotating winners. Top published winner Merck Canada Inc. has 6% of 99 similar awards.

Department buying calendar

JFMAMJJASOND

March highlighted (Canadian fiscal year-end). Spike not the peak month in this dataset.

Run an AI tender pre-check →

Buyer contact (contracting authority)

Eduardo Vides · luiseduardo.videslozano@forces.gc.ca · (873) 469-7365

Ottawa, Ontario · Advance contract award notice

As published on the CanadaBuys tender notice. Use for questions about this solicitation only.

View on Official Procurement Portal ↗

To submit a bid, you must respond through the official government procurement system.

Likely Competitors

Companies that won similar contracts (same category/department). Inferred from public award data — winners only.

Merck Canada Inc.

Won 6 similar contracts worth $283,611,072.15

$283,611,072.15
6 contracts
SANOFI PASTEUR LIMITED/SANOFI PASTEUR LIMITEE

Won 9 similar contracts worth $196,994,848.24

$196,994,848.24
9 contracts
Moderna Biopharma Canada Corporation

Won 1 similar contracts worth $160,635,561.65

$160,635,561.65
1 contracts
Pfizer Canada ULC

Won 3 similar contracts worth $114,354,630.52

$114,354,630.52
3 contracts
Emergent Product Development Gaithersburg Inc

Won 3 similar contracts worth $107,328,004.01

$107,328,004.01
3 contracts
Emergent BioSolutions Canada Inc.

Won 7 similar contracts worth $53,667,854.78

$53,667,854.78
7 contracts
Seqirus Canada Inc

Won 3 similar contracts worth $49,068,610.76

$49,068,610.76
3 contracts
GlaxoSmithKline Inc.

Won 9 similar contracts worth $48,865,590.72

$48,865,590.72
9 contracts
Elusys Therapeutics, Incorporated

Won 1 similar contracts worth $45,712,664.4

$45,712,664.4
1 contracts
Bavarian Nordic A/S

Won 4 similar contracts worth $34,830,923.1

$34,830,923.1
4 contracts